SD HEALTHCARE
Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
Medicine, Motivation Mix in New Network
Care: Incentives, Employer Participation Part of CoverageAn alternative to conventional health insurance is being marketed to San Diego-area employers with the promise of transparent medical costs, greater focus on physician-managed preventive care and potential savings to be shared by virtually everyone involved. September 22, 2016 3:26 p.m. $$ ShareSirenas LLC Wins $775,000 Grant From Bill & Melinda Gates Foundation
Biotech upstart Sirenas LLC has landed a $775,000 grant from the Bill & Melinda Gates Foundation to discover potential therapies to treat neglected diseases.
California Life Science Association Opens New LA Office
BIOTECH: It Will Partner to Promote, Enhance Sector in LA
Local trade group California Life Science Association is expanding its footprint to Los Angeles, with a new LA office and partnerships with LA BioMed and Lab Launch.
Virtual Exercise System Must Find Its Own Legs in Market
HEALTH: Product Offers Needed Care, Monitoring, And at Home Access
As pre-marketing activity goes, things look great for digital health-care company Reflexion Health Inc.: Its virtual exercise system scored a competitive federal grant, $18 million in new financing and demonstration projects in two states.
Tracon Pharmaceuticals Licenses Two Potential Cancer Therapies
Tracon Pharmaceuticals, a local public company, has licensed two potential cancer therapies from Johnson & Johnson’s Janssen Pharmaceuticals.
U.S. HealthWorks Offers to Bring Flu Shots to Businesses
Starting Oct. 1, San Diego-area employers with 25 or more workers may schedule a visit from a U.S. HealthWorks clinician who can provide on-site flu vaccinations and educational information.
Like BIOCOM, California Life Sciences Association Extends Reach into L.A.
Local trade group California Life Sciences Association is expanding its footprint to Los Angeles, with a new L.A. office and partnerships with LA BioMed and Lab Launch.
Franz Och Leaves Human Longevity for Illumina's Grail
Franz Och, a former Google executive recruited in 2014 by J. Craig Venter’s Human Longevity, has left the firm for an opportunity with Illumina-backed Grail.
Fortis Therapeutics Raises $18 Million in Series A Round
San Diego life science upstart Fortis Therapeutics Inc. has closed an $18 million Series A round led by local venture capital firm Avalon Ventures.
FDA Grants Orphan Drug Designation to Fate Therapeutics Product
Fate Therapeutics Inc.'s lead investigative product, ProTmune, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration.
National University, San Diego Co. Are Part of Telehealth Project
La Jolla-based National University announced it is collaborating with a pair of telehealth companies, including a locally based wireless device developer, to connect patients in Los Angeles County with nurse practitioners working remotely.
Imprimis Pharmaceuticals Cuts Staff, Closes Texas Facility
San Diego’s Imprimis Pharmaceuticals, a maker of compounded drugs, is reducing its expenses in hopes of reaching near-term profitability, the company announced Monday.
Scripps' Barbey Family Emergency and Trauma Center Set to Open Sept. 26
Scripps Health unveiled a $33 million, 33,000-square-foot emergency and trauma center set to open Sept. 26 on the first floor of the Prebys Cardiovascular Institute on the campus of Scripps Memorial Hospital La Jolla.
Allergan Buys Akarna Therapeutics for $50M
Pharmaceutical giant Allergan Plc has acquired Akarna Therapeutics Inc. for $50 million.
Apricus Biosciences Inc. Plans to Raise $4.6M in Direct Offering of Common Stock
San Diego biopharma Apricus Biosciences Inc. is expected to raise $4.6 million in a direct offering of its common stock to institutional investors, the company said Sept. 23.
Mast Terminates Clinical Development of Sickle Cell Drug Following Poor Results; Co.'s Stock Plunges
The stock of local biotech Mast Therapeutics Inc. has plummeted nearly 80 percent following news of lousy clinical trial results.
-
prev
- next
